The global narcolepsy drugs market has been under the spotlight recently as the awareness about sleep disorders grows. The pandemic brought with it a sudden wave of sleeping disorders as many found their daily schedules disrupted. Psychological distress added to the gamut of issues, which has raised awareness about narcolepsy too. As the focus on improving lifestyle in the post-pandemic world continues, analysts at Fairfield Market Research estimate the sentiment will drive the global narcolepsy drugs market.
According to the research report, the global narcolepsy drugs market is expected to be worth US$6,588.0 Mn by the end of 2026 from US$3,875.1 Mn in 2021. As the market grows with the positive sentiment of awareness and acceptance of drugs, it is poised to register a CAGR of 11.2% between 2026 and 2021.
Get a Sample Copy of Narcolepsy Drugs Market: https://www.fairfieldmarketresearch.com/report/narcolepsy-drugs-market
Narcolepsy with Cataplexy to Achieves Fastest-Growing Status
According to the Narcolepsy Network, about 70% of patients with narcolepsy experience cataplexy. It manifests in a sudden loss of muscle strength, resulting in slurred speech, jaw-dropping, drooping eyelids, and involuntary twitching amongst others. Cataplexy remains the confirming and conclusive diagnostic measurement of narcolepsy, making narcolepsy with cataplexy or type 1 narcolepsy the fastest-growing segment in the global market. Patients can experience this debilitating condition at a later stage as well. By the end of 2026, type 1 narcolepsy will hold 65% of the global market, predicts Fairfield Market Research.
Sodium Oxybate Remain Undisputed Drug for Treating Narcolepsy
Sodium oxybate is the unrivalled leading drug in the global narcolepsy drugs market. By the end of 2021, this drug is expected to hold a market share of 52% in the global market. This dominance can be attributed to its ability to treat cataplexy and excessive daytime sleepiness (EDS) is expected to bode well for the segment. Furthermore, it is the only drug approved by the US Food and Drug Administration (FDA) for treating cataplexy. Sold under the brand name Xyrem, sodium oxybate is best known to reduce the frequency of sleep attacks in patients with narcolepsy.
Stimulants such as modafinil, amodafonil, antidepressents, and tricuclical are also used in combination to treat narcolepsy. However, sodium oxybate’s results remain far better, giving the drug class an edge over others.
North America to Hold Lion’s Share in Global Narcolepsy Drugs Market
The National Institute of Neurological Disorders and Stroke, U.S., estimates that about 200,000 people living in the U.S. alone suffer from narcolepsy. Relatively higher awareness about the disorder, access to better healthcare, and increasing expenditure on medical needs are expected to drive the regional market between 2021 and 2026. Fairfield Market Research indicates that North America narcolepsy market will exhibit a CAGR of 11.3% from 2021 to 2025. Europe is expected to follow suit as the region experiences a demographic change that is dictated by information-centric patients.
Meanwhile, sleep disorders brought on by shift-based business models are expected to generate a demand for narcolepsy drugs in Asia Pacific. An overall increase in stress levels is also expected to underpin the growth of Asia Pacific narcolepsy drugs market.
Some of the leading players in the global narcolepsy drugs market are Avadel Pharmaceuticals plc, Harmony Biosciences, Arena Pharmaceuticals, Inc., Axsome Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., GrayMark Healtcare Inc., Ligand Pharmaceuticals, Inc., and Shionogi Inc.
For More Information Visit: https://www.fairfieldmarketresearch.com/report/narcolepsy-drugs-market
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Global Narcolepsy Market Research Report, By Type (Type 1, Type 2 Narcolepsy) Diagnosis (Poysomnogram, Multiple Sleep Latency Test) Treatment (Stimulants, Antidepressants, Sodium Oxybate) End Users (Hospitals, Retail Pharmacies) – Global Forecast Till 2027Market AnalysisThe global narcolepsy market is likely to grow at an 8.2% CAGR between 2017- 2023, according to the recent Market Research Future (MRFR) report.
It is characterized by automatic behaviors, cataplexy, excessive day time sleepiness, sleep paralysis, hallucination, and excessive sleepiness.
This disorder is caused by the lack of orexin, a brain chemical that regulates sleep.
These factors, as per the new MRFR report, include favorable reimbursement policies, increase in healthcare expenditure, increase in research and development activities for finding a cure for narcolepsy, extensive efforts undertaken by non-government and government organizations to spread awareness about narcolepsy, and growing demand for advanced therapies for sleeping disorders.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5701 Market Segmentation The MRFR report provides an inclusive segmental analysis of the global narcolepsy market based on end user, treatment, type, and diagnosis.
The stimulants segment is again segmented into armodafinil, modafinil, and others.
Global Blue Biotechnology Market To Project Significant Expansion At A CAGR of 10.2% During 2017-2023Market Synopsis:Blue biotechnology deals with the application of biotechnology to marine or aquatic sources at a molecular level to extract active new ingredients for development of new drugs and other purposes.
Market Research Future (MRFR) has published a report asserting that the global blue biotechnology market is anticipated to expand at a strong CAGR of 10.2% during the forecast period of 2017-2023.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/713Market Driver and Restraints:Oceans and Seas consist of large biodiversity and the development in the field of biotechnology has made it possible to utilize the marine and aquatic sources for obtaining various products that are useful for mankind.
The availability of large market for blue biotech products in the various sectors is majorly driving the global blue biotechnology market.The increasing demand for blue biotech products in the pharmaceutical industry for production of various medicines and drugs is fueling the expansion of the global blue biotechnology market.
The flexibility, adaptivity and constant development of blue biotechnology are widening its application range in various industries.Market Segmentation:The global blue biotechnology market has been segmented on the basis of product, application and end-users.
Based on end-users, the blue biotechnology market is segmented into hospitals, pharmaceutical companies, biotechnology companies, research institutes, laboratories, and others.
Lack of awareness and less technological penetration in the underdeveloped area is resulting in the slow growth of blue biotechnology market in the Middle East and Africa region.Competitive Analysis:The rapidly increasing research and development expenditure by the players for innovative product launch in medical, cosmetics, food and other industries is triggering competition in the global blue biotechnology market.
